Minocycline (MIN) usually shows good activity against Acinetobacter baumannii strains. The
reintroduction to the market of intravenous MIN provides an additional agent to the limited …

Minocycline-based combination therapy has been suggested to be a possible choice for the
treatment of infections caused by minocycline-susceptible Acinetobacter baumannii, but its …

Objectives The study investigated the effect of colistin and minocycline when tested singly
and in combination against Acinetobacter baumannii. Methods Thirteen unrelated imipenem …

Early studies in the 1970s showed that minocycline was an effective antibiotic for the
treatment of Acinetobacter-associated infections. At that time, most Acinetobacter baumannii …

Acinetobacter baumannii can cause life-threatening nosocomial infections associated with
high rates of morbidity and mortality. In recent years, the increasing number of infections due …

Antimicrobial resistance among Acinetobacter baumannii is increasing worldwide, often
necessitating combination therapy. The clinical utility of using minocycline with polymyxin B …

Among Acinetobacter species, A. baumannii and other closely related species are
commonly implicated in nosocomial infections. These organisms are usually multidrug …

Sir, Acinetobacter baumannii is a significant nosocomial pathogen, in particular in ICU
patients. Their multidrug resistance, propensity for clonal spread and involvement in hospital …

Minocycline is one of the few options available to treat infections caused by Acinetobacter
baumannii. Acquired resistance to minocycline in A. baumannii is associated with presence …

Intravenous minocycline (Minocin®) is approved in the USA for use in patients with
infections due to susceptible strains of Gram-positive and Gram-negative pathogens …